Table 1.
Clinical and biological analysis.
| Control | Sorafenib | Vevorisertib | Vevorisertib + Soraf | p-Value | |
|---|---|---|---|---|---|
| Body Weight (g) | 291 ± 5.0 | 290 ± 4.1 | 290 ± 3.3 | 281 ± 3.3 | 0.1520 |
| Liver | |||||
| Weight (g) | 13.0 ± 0.4 | 13.1 ± 0.3 | 13.1 ± 0.4 | 11.6 ± 0.6 | 0.0567 |
| TG (g/L) | 31.5 ± 4.9 | 26.6 ± 1.9 | 28.5 ± 2.5 | 26.3 ± 1.7 | 0.5783 |
| Blood | |||||
| Albumin (g/dL) | 3.5 ± 0.18 | 3.6 ± 0.06 | 3.6 ± 0.03 | 3.3 ±0.05 *, # | 0.0127 |
| AST (U/L) | 97.4 ± 5.9 | 90.2 ± 4.8 | 82.9 ± 2.9 | 75.3 ± 3.6 * | 0.0283 |
| ALT (U/L) | 69.3 ± 3.9 | 71.2 ± 3.4 | 61.8 ± 3.4 | 50.3 ± 3.0 *, ## | 0.0029 |
| ALP (U/L) | 199.2 ± 9.7 | 212.0 ± 7.6 | 184.6 ± 7.1 | 192.0 ± 5.7 | 0.1499 |
| GGT (U/L) | 14.0 ± 3.0 | 15.3 ± 2.1 | 7.7 ± 1.7 | 2.7 ± 1.1 *, ## | 0.0013 |
| PT (s) | 18.1 ± 0.5 | 19.2 ± 1.3 | 18.0 ± 0.3 | 18.5 ± 0.5 | 0.9013 |
| Total Bilirubin (mg/dL) | 0.25 ± 0.04 | 0.18 ± 0.01 | 0.15 ± 0.01 * | 0.14 ± 0.01 *** | 0.0002 |
| Creatinine (mg/dL) | 0.37 ± 0.02 | 0.33 ± 0.02 | 0.40 ± 0.01 | 0.31 ± 0.01 | 0.0700 |
| GLU (mg/dL) | 132.3 ± 7.8 | 141.1 ± 5.7 | 152.6 ± 7.0 | 140.0 ± 6.2 | 0.2618 |
| Cholesterol (mg/dL) | 84.4 ± 4.3 | 86.2 ± 3.0 | 102.6 ± 2.0 *, & | 84.7 ± 2.2 | 0.0044 |
| TG (g/L) | 78.4 ± 11.1 | 70.3 ± 10.7 | 54.0 ± 11.5 | 60.6 ± 13.1 | 0.4764 |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; PT, prothrombin time; GLU, glucose; TG, triglycerides. Values are means ± SE. Significant difference compared to control; *: p < 0.05; ***: p < 0.001. Significant difference compared to sorafenib; #: p < 0.05; ##: p < 0.01. Significant difference between vevorisertib + sorafenib and vevorisertib alone; &: p < 0.05. n = 7/group. The comparable biological analysis of 6 weeks old rats at T0 before DEN injections are: Albumin 3.23 ± 0.04 g/dL; AST 82.2 ± 8.68 U/L; ALT 53.2 ± 1.9 U/L; Total Bilirubin 0.17 ± 0.02 mg/dL; Creatinine 0.20 ± 0.00 mg/dL ([17]).